Publikationen von Kros, Johan M.

van den Bent, Martin J., Baumert, Brigitta, Erridge, Sara C., Vogelbaum, Michael A., Nowak, Anna K. , Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M., Baurain, Jean Francais, Mason, Warren P., Wheeler, Helen, Chinot, Olivier L., Gill, Sanjeev, Griffin, Matthew, Brachman, David G., Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H., Weber, Damien C., Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Pascoe, Sarah, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, van Heuvel, Irene, Stupp, Roger, Aldape, Ken, Jenkins, Robert B., Dubbink, Hendrikus Jan, Dinjens, Winand N. M., Wesseling, Pieter , Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, Wick, Wolfgang und Kros, Johan M. (2017) Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet 390 (10103), S. 1645-1653. Volltext nicht vorhanden.

Hegi, Monika E., Diserens, Annie-Claire, Gorlia, Thierry, Hamou, Marie-France, de Tribolet, Nicolas, Weller, Michael, Kros, Johan M., Hainfellner, Johannes A., Mason, Warren, Mariani, Luigi, Bromberg, Jacoline E. C., Hau, Peter, Mirimanoff, René O., Cairncross, J. Gregory, Janzer, Robert C. und Stupp, Roger (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine 352 (10), S. 997-1003. Volltext nicht vorhanden.